| Chronic Obstructive Airway Disease
Incruse Ellipta vs Tudorza Pressair
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Incruse Ellipta vs Tudorza Pressair with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTudorza Pressair has a higher rate of injection site reactions vs Incruse Ellipta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tudorza Pressair but not Incruse Ellipta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Incruse Ellipta
Tudorza Pressair
At A Glance
Oral inhalation
Once daily
Long-acting muscarinic antagonist
Oral inhalation
Twice daily
Anticholinergic
Indications
- Chronic Obstructive Airway Disease
- Chronic Obstructive Airway Disease
Dosing
Chronic Obstructive Airway Disease 1 actuation (umeclidinium 62.5 mcg) once daily by oral inhalation; use at the same time every day; do not use more than 1 time every 24 hours. No dosage adjustment required for geriatric patients, patients with renal impairment, or patients with moderate hepatic impairment.
Chronic Obstructive Airway Disease One oral inhalation of 400 mcg twice daily (morning and evening approximately 12 hours apart).
Contraindications
- Severe hypersensitivity to milk proteins
- Hypersensitivity to umeclidinium or any of the excipients
- Severe hypersensitivity to milk proteins
- Hypersensitivity to aclidinium bromide or any excipient
Adverse Reactions
Most common (>=1%) Nasopharyngitis, upper respiratory tract infection, cough, arthralgia, pharyngitis, viral upper respiratory tract infection, myalgia, abdominal pain upper, toothache, contusion, tachycardia
Serious Paradoxical bronchospasm, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Eye pain, glaucoma, vision blurred, anaphylaxis, angioedema, pruritus, urticaria, dysuria, urinary retention, dysphonia, oropharyngeal pain
Most common (>=1%) Headache, nasopharyngitis, cough, diarrhea, sinusitis, rhinitis, toothache, fall, vomiting
Serious Paradoxical bronchospasm, worsening of narrow-angle glaucoma, worsening of urinary retention, immediate hypersensitivity reactions
Postmarketing Anaphylaxis, angioedema, urticaria, rash, bronchospasm, itching, nausea, dysphonia, blurred vision, urinary retention, tachycardia, stomatitis
Pharmacology
Long-acting muscarinic antagonist (LAMA/anticholinergic); competitively and reversibly inhibits M3 receptors at airway smooth muscle to produce bronchodilation lasting longer than 24 hours after once-daily oral inhalation.
Aclidinium bromide is a long-acting antimuscarinic (anticholinergic) agent that inhibits M3 muscarinic receptors on airway smooth muscle, causing bronchodilation; the bronchodilatory effect is predominantly site-specific following inhalation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Incruse Ellipta
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (9/12)
Tudorza Pressair
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Incruse Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Tudorza Pressair
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (0/8)
Humana
Incruse Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Tudorza Pressair
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Incruse Ellipta.
No savings programs available for Tudorza Pressair.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Incruse ElliptaView full Incruse Ellipta profile
Tudorza PressairView full Tudorza Pressair profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.